<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="220800">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209274</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol #0401</org_study_id>
    <secondary_id>Protocol #0401</secondary_id>
    <nct_id>NCT00209274</nct_id>
  </id_info>
  <brief_title>Pivotal Study of a Percutaneous Mitral Valve Repair System</brief_title>
  <acronym>EVERESTIIRCT</acronym>
  <official_title>Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evalve</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evalve</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EVEREST II Randomized Controlled Trial (RCT) is a prospective, multi-center, randomized
      study of the MitraClip® System in the treatment of mitral valve regurgitation, randomizing
      patients to MitraClip or mitral valve surgery. The EVEREST II High Risk Registry (HRR) study
      is a prospective multi-center study of the MitraClip System for the treatment of mitral
      valve regurgitation in high surgical risk patients. Enrollment in the RCT and HRR is closed.
      A continued access prospective, multi-center study (REALISM) of the MitraClip System in a
      surgical population (non-high risk arm) and a high surgical risk population (high risk arm)
      is ongoing. Enrollment in the non-high risk arm of REALISM is closed. Enrollment in the high
      risk arm of REALISM is ongoing. Patients enrolled in EVEREST II undergo 30-day, 6-month,
      12-month, 18-month and 24-month clinical and echocardiographic follow-up, and then annually
      for 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, randomized study of the safety and effectiveness of an
      endovascular approach to the treatment of mitral valve regurgitation using the Evalve
      Cardiovascular Valve Repair System (MitraClip® implant).

      A minimum of 279 evaluable patients randomized 2:1 to MitraClip or mitral valve surgery,
      respectively, are required to test the primary safety and effectiveness endpoints of the
      RCT. Enrollment in the RCT is now complete. 60 roll-in patients were enrolled under EVEREST
      II RCT.

      38 clinical sites throughout the US and Canada have participated in the RCT and HRR. 37 US
      sites are participating in REALISM.

      The RCT is powered to test the hypothesis MitraClip has both superiority of safety and
      non-inferiority of effectiveness compared to mitral valve repair or replacement surgery. The
      HRR is powered to show lower mortality at 30 days with the MitraClip than predicted surgical
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from surgery for valve dysfunction, death, and moderate to severe (3+) or severe (4+) mitral regurgitation (MR).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>defined as a combined clinical endpoint of death, myocardial infarction, reoperation for failed surgical repair or replacement, nonelective cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, ventilation for greater than 48 hours, gastrointestinal (GI) complication requiring surgery, new onset of permanent atrial fibrillation, septicemia, and transfusion of 2 or more units of blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse events (MAE)</measure>
    <time_frame>12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding complications.</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Major Bleeding Complications defined as procedure related bleeding that requires a transfusion of ≥2 units of blood products and/or surgical intervention at 30 days or hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cerebral thromboembolism.</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Defined as any thrombus or thromboembolism in the vasculature (excluding central nervous system events) or on the investigational device or any commercially available implant used during surgery confirmed by standard clinical and laboratory testing and which requires treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocarditis.</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Defined as a diagnosis of endocarditis based on the Duke criteria.From The American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines for the Management of Patients with Valvular Heart Disease, Journal of the American College of Cardiology (JACC), Vol 32, No.5,November 1, 1998:pg1541, Table 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis.</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Defined as evidence of the formation of an independently moving thrombus on any part of the MitraClip or any commercially available implant used during surgery by echocardiography or fluoroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemolysis.</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Defined as new onset of anemia associated with laboratory evidence of red cell destruction. Diagnosed when plasma free hemoglobin is greater than 40 mg/dL on repeat measures within 24 hours or on one measure if intervention is initiated based on other clinical symptoms.
Reported as major or minor as defined below:
Major: Requires intervention with red blood cell transfusion or other hematocrit increasing measures in the absence of other obvious bleeding. Minor: Does not require intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant Atrial septal defect (ASD).</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Defined as a significant residual atrial septal opening. Reported as clinically significant if intervention is performed for the primary purpose of repairing the ASD. If cardiac surgery is indicated for reasons other than residual ASD (e.g., residual MR) and the ASD is repaired at the same time, this does not meet the definition of clinically significant ASD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Valve stenosis.</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Defined as a mitral valve planimetered orifice area of less than 1.5 cm2 as measured by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class cardiac disease.</measure>
    <time_frame>30 days, 6 months and 12 months</time_frame>
    <description>Class I Patients with cardiac disease but without resulting limitations of physical activity. Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain. Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain. Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as successful MitraClip implantation with resulting MR of 2+ or less.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure length of hospital stay.</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure intensive care unit (ICU) / critical care unit (CCU)/(post-anesthesia care unit) PACU duration.</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (SF)-36 Quality of Life questionnaire.</measure>
    <time_frame>30 days and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAE in patients over 75 years of age.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral valve repair success.</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as freedom from mitral valve replacement surgery for Valve Dysfunction, death, re-operation, and MR &gt; 2+ at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as successful implant of the Clip(s) with resulting MR severity ≤ 2 at discharge or 1 grade MR reduction at discharge accompanied by 1 level NYHA reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from surgery for valve dysfunction, death, and moderate to severe (3+) or severe (4+) mitral regurgitation.</measure>
    <time_frame>18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clip implant rate</measure>
    <time_frame>Day 0</time_frame>
    <description>defined as the rate of successful implantation of MitraClip(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural freedom from MAE.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute surgical success</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as successful mitral valve repair or replacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Status</measure>
    <time_frame>30 days and 12 months</time_frame>
    <description>Left Ventricular Status is defined a including including Left ventricular (LV) ejection fraction (EF), LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV internal dimension systole (LVIDs), and LV internal dimension diastole (LVIDd) as determined by the core echo laboratory at 30 days or hospital discharge, whichever is longer, and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospital readmissions for congestive heart failure (CHF).</measure>
    <time_frame>12 months pre- versus post-MitraClip</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days hospitalized for CHF.</measure>
    <time_frame>12 months pre- versus post-MitraClip</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test.</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular</measure>
    <time_frame>30 days and 12 months.</time_frame>
    <description>Vascular Complications defined as the occurrence of any of the following resulting through 30 days or hospital discharge, whichever is longer:
Hematoma at access site &gt;6 cm.;
Retroperitoneal hematoma;
Arteriovenous (AV) fistula;
Symptomatic peripheral ischemia/ nerve injury or the clinical signs or symptoms lasting &gt;48 hours;
Vascular Surgical Repair at catheter access sites;
Pulmonary embolism;
Ipsilateral deep vein thrombus; or
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiac output</measure>
    <time_frame>30 days and 12 months</time_frame>
    <description>Cardiac output as measured by core lab echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac index</measure>
    <time_frame>30 days and 12 months</time_frame>
    <description>Defined as cardiac index (cardiac output divided by body surface area) as measured by core lab echocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of new Coumadin (warfarin) usage</measure>
    <time_frame>30 days and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of discharge to a nursing home or skilled nursing facility.</measure>
    <time_frame>30 Days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve index</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as mitral valve area divided by body surface area as measured by core lab echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve area</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as mitral valve area as measured by core lab echocardiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transvalvular flow gradient</measure>
    <time_frame>30 Days</time_frame>
    <description>Peak and Mean</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant volume</measure>
    <time_frame>30 Days</time_frame>
    <description>Regurgitant volume as determined by the core echo laboratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant fraction</measure>
    <time_frame>30 Days</time_frame>
    <description>Regurgitant fraction as determined by the core echo laboratory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of mitral valve replacement</measure>
    <time_frame>30 Days and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospital re-admissions</measure>
    <time_frame>30 Days and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1317</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Mitral Valve Incompetence</condition>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous mitral valve repair using MitraClip implant. The expected number of patients in the device arm is 186 (172 evaluable)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitral valve repair or replacement surgery.The expected number of patients in the active comparator arm is 93 (86 evaluable).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous mitral valve repair using MitraClip implant</intervention_name>
    <description>MitraClip Implant</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MitraClip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mitral valve repair or replacement surgery</intervention_name>
    <description>Repair or replacement of mitral valve</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion/Exclusion Criteria:

        Patients with Grade 3 (moderate to severe) or Grade 4 (severe) mitral regurgitation (MR)
        based on American Society of Echocardiography guidelines:

          -  Are 18 years or older.

          -  Symptomatic

          -  If asymptomatic, must have new onset of atrial fibrillation, pulmonary hypertension,
             or evidence of left ventricular dysfunction

          -  Are candidates for mitral valve surgery

          -  Are candidates for transseptal catheterization

          -  Primary regurgitant jet must originate from malcoaptation of the A2 and P2 scallops
             of the mitral valve

          -  Appropriate valve anatomy for MitraClip

          -  Does not need other cardiac surgery or any emergency surgery

          -  Did not experience myocardial infarction in prior 12 weeks or endovascular procedure
             in prior 30 days

          -  Mitral valve orifice area ≥ 4 cm2

          -  Do not have renal insufficiency

          -  Echocardiographic evidence of intracardiac mass, thrombus or vegetation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted Feldman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald G Glower Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fann JI, St Goar FG, Komtebedde J, Oz MC, Block PC, Foster E, Butany J, Feldman T, Burdon TA. Beating heart catheter-based edge-to-edge mitral valve procedure in a porcine model: efficacy and healing response. Circulation. 2004 Aug 24;110(8):988-93. Epub 2004 Aug 9.</citation>
    <PMID>15302782</PMID>
  </reference>
  <reference>
    <citation>St Goar FG, Fann JI, Komtebedde J, Foster E, Oz MC, Fogarty TJ, Feldman T, Block PC. Endovascular edge-to-edge mitral valve repair: short-term results in a porcine model. Circulation. 2003 Oct 21;108(16):1990-3. Epub 2003 Oct 6.</citation>
    <PMID>14530193</PMID>
  </reference>
  <reference>
    <citation>Borgia F, Di Mario C, Franzen O. Adenosine-induced asystole to facilitate MitraClip placement in a patient with adverse mitral valve morphology. Heart. 2011 May;97(10):864. doi: 10.1136/hrt.2010.208132. Epub 2010 Oct 29.</citation>
    <PMID>21036802</PMID>
  </reference>
  <reference>
    <citation>Tamburino C, Immè S, Barbanti M, Mulè M, Pistritto AM, Aruta P, Cammalleri V, Scarabelli M, Mangiafico S, Scandura S, Ussia GP. Reduction of mitral valve regurgitation with Mitraclip® percutaneous system. Minerva Cardioangiol. 2010 Oct;58(5):589-98.</citation>
    <PMID>20948505</PMID>
  </reference>
  <reference>
    <citation>Lim DS, Kunjummen BJ, Smalling R. Mitral valve repair with the MitraClip device after prior surgical mitral annuloplasty. Catheter Cardiovasc Interv. 2010 Sep 1;76(3):455-9. doi: 10.1002/ccd.22547.</citation>
    <PMID>20839359</PMID>
  </reference>
  <reference>
    <citation>Tamburino C, Ussia GP, Maisano F, Capodanno D, La Canna G, Scandura S, Colombo A, Giacomini A, Michev I, Mangiafico S, Cammalleri V, Barbanti M, Alfieri O. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J. 2010 Jun;31(11):1382-9. doi: 10.1093/eurheartj/ehq051. Epub 2010 Mar 18.</citation>
    <PMID>20299349</PMID>
  </reference>
  <reference>
    <citation>Argenziano M, Skipper E, Heimansohn D, Letsou GV, Woo YJ, Kron I, Alexander J, Cleveland J, Kong B, Davidson M, Vassiliades T, Krieger K, Sako E, Tibi P, Galloway A, Foster E, Feldman T, Glower D; EVEREST Investigators.. Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg. 2010 Jan;89(1):72-80; discussion p 80. doi: 10.1016/j.athoracsur.2009.08.063.</citation>
    <PMID>20103209</PMID>
  </reference>
  <reference>
    <citation>Rogers JH, Yeo KK, Carroll JD, Cleveland J, Reece TB, Gillinov AM, Rodriguez L, Whitlow P, Woo YJ, Herrmann HC, Young JN. Late surgical mitral valve repair after percutaneous repair with the MitraClip system. J Card Surg. 2009 Nov-Dec;24(6):677-81. doi: 10.1111/j.1540-8191.2009.00901.x. Epub 2009 Jul 24.</citation>
    <PMID>19682161</PMID>
  </reference>
  <reference>
    <citation>Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, Lim S, Foster E, Glower D; EVEREST Investigators.. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009 Aug 18;54(8):686-94. doi: 10.1016/j.jacc.2009.03.077.</citation>
    <PMID>19679246</PMID>
  </reference>
  <reference>
    <citation>Herrmann HC, Kar S, Siegel R, Fail P, Loghin C, Lim S, Hahn R, Rogers JH, Bommer WJ, Wang A, Berke A, Lerakis S, Kramer P, Wong SC, Foster E, Glower D, Feldman T; EVEREST Investigators.. Effect of percutaneous mitral repair with the MitraClip device on mitral valve area and gradient. EuroIntervention. 2009 Jan;4(4):437-42.</citation>
    <PMID>19284064</PMID>
  </reference>
  <reference>
    <citation>Luk A, Butany J, Ahn E, Fann JI, St Goar F, Thornton T, McDermott L, Madayag C, Komtebedde J. Mitral repair with the Evalve MitraClip device: histopathologic findings in the porcine model. Cardiovasc Pathol. 2009 Sep-Oct;18(5):279-85. doi: 10.1016/j.carpath.2008.07.001. Epub 2008 Aug 13.</citation>
    <PMID>18703359</PMID>
  </reference>
  <reference>
    <citation>Pope NH, Lim S, Ailawadi G. Late calcific mitral stenosis after MitraClip procedure in a dialysis-dependent patient. Ann Thorac Surg. 2013 May;95(5):e113-4. doi: 10.1016/j.athoracsur.2012.10.067.</citation>
    <PMID>23608290</PMID>
  </reference>
  <reference>
    <citation>Cikirikcioglu M, Cherian S, Schussler O, Kalangos A. Regarding &quot;The EVEREST II Trial: design and rationale for a randomized study of the Evalve MitraClip system compared with mitral valve surgery for mitral regurgitation&quot;. Am Heart J. 2011 Jul;162(1):e11-2; author reply e13. doi: 10.1016/j.ahj.2011.04.004. Epub 2011 Jun 12.</citation>
    <PMID>21742074</PMID>
  </reference>
  <reference>
    <citation>Condado JA, Vélez-Gimón M. Catheter-based approach to mitral regurgitation. J Interv Cardiol. 2003 Dec;16(6):523-34. Review.</citation>
    <PMID>14632950</PMID>
  </reference>
  <reference>
    <citation>Fann JI, St Goar FG. Percutaneous aortic valve replacement and mitral valve repair. Future Cardiol. 2005 May;1(3):393-403. doi: 10.1517/14796678.1.3.393.</citation>
    <PMID>19804122</PMID>
  </reference>
  <reference>
    <citation>Cohn LH. Percutaneous mitral valve repair with the edge-to-edge technique: a surgeon's perspective. J Am Coll Cardiol. 2005 Dec 6;46(11):2141-2. Epub 2005 Oct 17.</citation>
    <PMID>16325054</PMID>
  </reference>
  <reference>
    <citation>Condado JA, Acquatella H, Rodriguez L, Whitlow P, Vélez-Gimo M, St Goar FG. Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv. 2006 Feb;67(2):323-5.</citation>
    <PMID>16419054</PMID>
  </reference>
  <reference>
    <citation>Feldman T, Glower D. Patient selection for percutaneous mitral valve repair: insight from early clinical trial applications. Nat Clin Pract Cardiovasc Med. 2008 Feb;5(2):84-90. doi: 10.1038/ncpcardio1068. Review.</citation>
    <PMID>18223540</PMID>
  </reference>
  <reference>
    <citation>Biner S, Siegel RJ, Feldman T, Rafique AM, Trento A, Whitlow P, Rogers J, Moon M, Lindman B, Zajarias A, Glower D, Kar S; EVEREST investigators.. Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. Eur J Heart Fail. 2012 Aug;14(8):939-45. Epub 2012 May 14.</citation>
    <PMID>22588322</PMID>
  </reference>
  <results_reference>
    <citation>Dang NC, Aboodi MS, Sakaguchi T, Wasserman HS, Argenziano M, Cosgrove DM, Rosengart TK, Feldman T, Block PC, Oz MC. Surgical revision after percutaneous mitral valve repair with a clip: initial multicenter experience. Ann Thorac Surg. 2005 Dec;80(6):2338-42.</citation>
    <PMID>16305903</PMID>
  </results_reference>
  <results_reference>
    <citation>Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, St Goar F, Rodriguez L, Silvestry F, Schwartz A, Sanborn TA, Condado JA, Foster E. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005 Dec 6;46(11):2134-40. Epub 2005 Oct 19.</citation>
    <PMID>16325053</PMID>
  </results_reference>
  <results_reference>
    <citation>Herrmann HC, Rohatgi S, Wasserman HS, Block P, Gray W, Hamilton A, Zunamon A, Homma S, Di Tullio MR, Kraybill K, Merlino J, Martin R, Rodriguez L, Stewart WJ, Whitlow P, Wiegers SE, Silvestry FE, Foster E, Feldman T. Mitral valve hemodynamic effects of percutaneous edge-to-edge repair with the MitraClip device for mitral regurgitation. Catheter Cardiovasc Interv. 2006 Dec;68(6):821-8.</citation>
    <PMID>17080467</PMID>
  </results_reference>
  <results_reference>
    <citation>Silvestry FE, Rodriguez LL, Herrmann HC, Rohatgi S, Weiss SJ, Stewart WJ, Homma S, Goyal N, Pulerwitz T, Zunamon A, Hamilton A, Merlino J, Martin R, Krabill K, Block PC, Whitlow P, Tuzcu EM, Kapadia S, Gray WA, Reisman M, Wasserman H, Schwartz A, Foster E, Feldman T, Wiegers SE. Echocardiographic guidance and assessment of percutaneous repair for mitral regurgitation with the Evalve MitraClip: lessons learned from EVEREST I. J Am Soc Echocardiogr. 2007 Oct;20(10):1131-40. Epub 2007 Jun 13.</citation>
    <PMID>17570634</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri L, Garg P, Massaro JM, Foster E, Glower D, Mehoudar P, Powell F, Komtebedde J, McDermott E, Feldman T. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J. 2010 Jul;160(1):23-9. doi: 10.1016/j.ahj.2010.04.009.</citation>
    <PMID>20598968</PMID>
  </results_reference>
  <results_reference>
    <citation>Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, Bajwa T, Herrmann HC, Lasala J, Maddux JT, Tuzcu M, Kapadia S, Trento A, Siegel RJ, Foster E, Glower D, Mauri L, Kar S; EVEREST II Investigators.. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012 Jan 10;59(2):130-9. doi: 10.1016/j.jacc.2011.08.067.</citation>
    <PMID>22222076</PMID>
  </results_reference>
  <results_reference>
    <citation>Herrmann HC, Gertz ZM, Silvestry FE, Wiegers SE, Woo YJ, Hermiller J, Segar D, Heimansohn D, Gray W, Homma S, Argenziano M, Wang A, Jollis J, Lampert MB, Alexander J, Mauri L, Foster E, Glower D, Feldman T. Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial. J Am Coll Cardiol. 2012 Apr 3;59(14):1312-9. doi: 10.1016/j.jacc.2011.12.023.</citation>
    <PMID>22464260</PMID>
  </results_reference>
  <results_reference>
    <citation>Glower D, Ailawadi G, Argenziano M, Mack M, Trento A, Wang A, Lim DS, Gray W, Grayburn P, Dent J, Gillam L, Sethuraman B, Feldman T, Foster E, Mauri L, Kron I; EVEREST II Investigators.. EVEREST II randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure. J Thorac Cardiovasc Surg. 2012 Apr;143(4 Suppl):S60-3. doi: 10.1016/j.jtcvs.2012.01.047.</citation>
    <PMID>22423604</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith T, McGinty P, Bommer W, Low RI, Lim S, Fail P, Rogers JH. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv. 2012 Oct 1;80(4):678-85. doi: 10.1002/ccd.23485. Epub 2012 Mar 15.</citation>
    <PMID>22422577</PMID>
  </results_reference>
  <results_reference>
    <citation>Mauri L, Foster E, Glower DD, Apruzzese P, Massaro JM, Herrmann HC, Hermiller J, Gray W, Wang A, Pedersen WR, Bajwa T, Lasala J, Low R, Grayburn P, Feldman T; EVEREST II Investigators.. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. 2013 Jul 23;62(4):317-28. doi: 10.1016/j.jacc.2013.04.030. Epub 2013 May 9.</citation>
    <PMID>23665364</PMID>
  </results_reference>
  <results_reference>
    <citation>Foster E, Kwan D, Feldman T, Weissman NJ, Grayburn PA, Schwartz A, Rogers JH, Kar S, Rinaldi MJ, Fail PS, Hermiller J, Whitlow PL, Herrmann HC, Lim DS, Glower DD; EVEREST Investigators.. Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. Circ Cardiovasc Imaging. 2013 Jul;6(4):522-30. doi: 10.1161/CIRCIMAGING.112.000098. Epub 2013 Apr 30.</citation>
    <PMID>23633132</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 17, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <firstreceived_results_disposition_date>July 31, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Mitral Valve Incompetence</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Mitral Insufficiency</keyword>
  <keyword>Mitral Valve</keyword>
  <keyword>MR</keyword>
  <keyword>Mitral Valve Prolapse</keyword>
  <keyword>Edge to Edge (E2E)</keyword>
  <keyword>Alfieri Technique</keyword>
  <keyword>MitraClip</keyword>
  <keyword>Functional MR</keyword>
  <keyword>Degenerative MR</keyword>
  <keyword>Echocardiogram</keyword>
  <keyword>CAD - Coronary Artery Disease</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>EVEREST</keyword>
  <keyword>EVEREST I</keyword>
  <keyword>EVEREST II</keyword>
  <keyword>REALISM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
